$APYX
Apyx Medical Corp Stock $apyx

$apyx Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000071913520000076 Filed on November 09, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q3
Revenue	$11.46M	$6.954M	$7.575M
YoY Change	36.72%	-8.2%	106.29%
Cost Of Revenue	$3.760M	$2.229M	$2.281M
YoY Change	57.98%	-2.28%	98.18%
Gross Profit	$7.700M	$4.725M	$5.294M
YoY Change	38.41%	-10.75%	110.0%
Gross Profit Margin	67.19%	67.95%	69.89%
Selling, General & Admin	$8.840M	$2.706M	$3.836M
YoY Change	-19.05%	-29.46%	102.11%
% of Gross Profit	114.81%	57.27%	72.46%
Research & Development	$920.0K	$1.047M	$1.016M
YoY Change	-16.36%	3.05%	65.74%
% of Gross Profit	11.95%	22.16%	19.19%
Depreciation & Amortization	$230.0K	$220.0K	$190.0K
YoY Change	-4.17%	15.79%	227.59%
% of Gross Profit	2.99%	4.66%	3.59%
Operating Expenses	$9.760M	$9.096M	$10.05M
YoY Change	-18.8%	-9.49%	89.3%
Operating Profit	-$2.060M	-$4.371M	-$4.756M
YoY Change	-68.1%	-8.1%	70.59%
Interest Expense	$0.00	$25.00K	$0.00
YoY Change	-100.0%		-100.0%
% of Operating Profit
Other Income/Expense, Net	$130.0K	-$78.00K	$557.0K
YoY Change	-136.11%	-114.0%	-173.0%
Pretax Income	-$1.920M	-$4.449M	-$4.199M
YoY Change	-68.32%	5.95%	18.25%
Income Tax	$3.270M	-$715.0K	$171.0K
% Of Pretax Income
Net Earnings	-$1.530M	-$3.728M	-$4.370M
YoY Change	-73.67%	-14.69%	-106.38%
Net Earnings / Revenue	-13.35%	-53.61%	-57.69%
Basic Earnings Per Share		-$0.11	-$0.13
Diluted Earnings Per Share	-$44.65K	-$0.11	-$0.13
COMMON SHARES
Basic Shares Outstanding	34.27M shares	34.22M shares	33.92M shares
Diluted Shares Outstanding		34.22M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$41.90M	$43.50M	$62.30M
YoY Change	-28.74%	-30.18%	-35.17%
Cash & Equivalents	$41.92M	$43.54M	$62.27M
Short-Term Investments			$0.00
Other Short-Term Assets	$2.800M	$4.200M	$1.700M
YoY Change	-22.22%	147.06%	183.33%
Inventory	$4.051M	$5.416M	$7.237M
Prepaid Expenses
Receivables	$8.399M	$6.154M	$7.662M
Other Receivables	$1.275M	$1.158M	$0.00
Total Short-Term Assets	$66.09M	$67.66M	$78.91M
YoY Change	-13.87%	-14.25%	-26.22%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.541M	$6.348M	$6.645M
YoY Change	-1.16%	-4.47%	13.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$807.0K	$508.0K	$387.0K
YoY Change	106.39%	31.27%	0.52%
Total Long-Term Assets	$8.022M	$7.751M	$8.038M
YoY Change	0.12%	-3.57%	29.08%
TOTAL ASSETS
Total Short-Term Assets	$66.09M	$67.66M	$78.91M
Total Long-Term Assets	$8.022M	$7.751M	$8.038M
Total Assets	$74.11M	$75.42M	$86.94M
YoY Change	-12.55%	-13.26%	-23.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.511M	$2.479M	$1.457M
YoY Change	-38.02%	70.14%	-37.95%
Accrued Expenses	$7.278M	$6.588M	$7.285M
YoY Change	-22.54%	-9.57%	-63.73%
Deferred Revenue	$0.00
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$200.0K	$400.0K	$200.0K
YoY Change	-50.0%	100.0%
Total Short-Term Liabilities	$9.153M	$9.594M	$9.039M
YoY Change	-25.65%	6.14%	-59.71%
LONG-TERM LIABILITIES
Long-Term Debt	$200.0K	$300.0K	$600.0K
YoY Change	-50.0%	-50.0%
Other Long-Term Liabilities	$166.0K	$400.0K	$600.0K
YoY Change	45.61%	-33.33%
Total Long-Term Liabilities	$166.0K	$400.0K	$1.200M
YoY Change	45.61%	-66.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.153M	$9.594M	$9.039M
Total Long-Term Liabilities	$166.0K	$400.0K	$1.200M
Total Liabilities	$10.25M	$11.08M	$10.21M
YoY Change	-23.98%	8.49%	-54.77%
SHAREHOLDERS EQUITY
Retained Earnings	$2.621M	$4.148M	$19.95M
YoY Change	-81.95%	-79.21%	-48.54%
Common Stock	$34.00K	$34.00K	$34.00K
YoY Change	0.0%	0.0%	3.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$63.72M	$64.20M	$76.73M
YoY Change
Total Liabilities & Shareholders Equity	$74.11M	$75.42M	$86.94M
YoY Change	-12.55%	-13.26%	-23.18%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q3
OPERATING ACTIVITIES
Net Income	-$1.530M	-$3.728M	-$4.370M
YoY Change	-73.67%	-14.69%	-106.38%
Depreciation, Depletion And Amortization	$230.0K	$220.0K	$190.0K
YoY Change	-4.17%	15.79%	227.59%
Cash From Operating Activities	-$1.020M	-$2.620M	-$4.540M
YoY Change	-68.71%	-42.29%	291.38%
INVESTING ACTIVITIES
Capital Expenditures	-$390.0K	-$10.00K	-$560.0K
YoY Change	77.27%	-98.21%	-530.77%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$390.0K	-$10.00K	-$550.0K
YoY Change	69.57%	-98.18%	-101.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-130.0K	110.0K	30.00K
YoY Change		266.67%	-101.2%
NET CHANGE
Cash From Operating Activities	-1.020M	-2.620M	-4.540M
Cash From Investing Activities	-390.0K	-10.00K	-550.0K
Cash From Financing Activities	-130.0K	110.0K	30.00K
Net Change In Cash	-1.540M	-2.520M	-5.060M
YoY Change	-55.87%	-50.2%	-115.75%
FREE CASH FLOW
Cash From Operating Activities	-$1.020M	-$2.620M	-$4.540M
Capital Expenditures	-$390.0K	-$10.00K	-$560.0K
Free Cash Flow	-$630.0K	-$2.610M	-$3.980M
YoY Change	-79.28%	-34.42%	208.53%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000719135
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	0-12183
	dei	Entity Registrant Name EntityRegistrantName	APYX MEDICAL CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2644611
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5115 Ulmerton Road,
	dei	Entity Address City Or Town EntityAddressCityOrTown	Clearwater
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33760
	dei	City Area Code CityAreaCode	727
	dei	Local Phone Number LocalPhoneNumber	384-2323
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	APYX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34274771	shares
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43539000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58812000	USD
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	760000	USD
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	273000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6154000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7987000	USD
CY2020Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7238000	USD
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	426000	USD
CY2020Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1158000	USD
CY2019Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1233000	USD
CY2020Q3	apyx	Provision For Obsolescence Inventory ProvisionForObsolescenceInventory	537000	USD
CY2019Q4	apyx	Provision For Obsolescence Inventory ProvisionForObsolescenceInventory	392000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	5416000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	5068000	USD
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4159000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3207000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	67664000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	76733000	USD
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4677000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4403000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6348000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6618000	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	266000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	350000	USD
CY2020Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	629000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	653000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	508000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	391000	USD
CY2020Q3	us-gaap	Assets Assets	75415000	USD
CY2019Q4	us-gaap	Assets Assets	84745000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2479000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2438000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6588000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9396000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	118000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	108000	USD
CY2020Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	269000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	229000	USD
CY2020Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	140000	USD
CY2019Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	140000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9594000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12311000	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	153000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	235000	USD
CY2020Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	347000	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	421000	USD
CY2020Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	583000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	405000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	400000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	114000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	11077000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	13486000	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34222505	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34222505	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34312527	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34169952	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	34000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	34000	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	60014000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	56708000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	4148000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	14517000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	64196000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	71259000	USD
CY2020Q3	us-gaap	Minority Interest MinorityInterest	142000	USD
CY2019Q4	us-gaap	Minority Interest MinorityInterest	0	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	64338000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71259000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	75415000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	84745000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6954000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7575000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16247000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19853000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2229000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2281000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6444000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6322000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	4725000	USD
CY2019Q3	us-gaap	Gross Profit GrossProfit	5294000	USD
	us-gaap	Gross Profit GrossProfit	9803000	USD
	us-gaap	Gross Profit GrossProfit	13531000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1047000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1016000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3002000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2634000	USD
CY2020Q3	us-gaap	Professional Fees ProfessionalFees	1835000	USD
CY2019Q3	us-gaap	Professional Fees ProfessionalFees	2039000	USD
	us-gaap	Professional Fees ProfessionalFees	5882000	USD
	us-gaap	Professional Fees ProfessionalFees	5818000	USD
CY2020Q3	us-gaap	Salaries And Wages SalariesAndWages	3508000	USD
CY2019Q3	us-gaap	Salaries And Wages SalariesAndWages	3159000	USD
	us-gaap	Salaries And Wages SalariesAndWages	10258000	USD
	us-gaap	Salaries And Wages SalariesAndWages	10157000	USD
CY2019Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3836000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2706000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8691000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9830000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	9096000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	10050000	USD
	us-gaap	Operating Expenses OperatingExpenses	27833000	USD
	us-gaap	Operating Expenses OperatingExpenses	28439000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4371000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4756000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18030000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14908000	USD
CY2020Q3	us-gaap	Interest Income Operating InterestIncomeOperating	10000	USD
CY2019Q3	us-gaap	Interest Income Operating InterestIncomeOperating	327000	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	1153000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	25000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2020Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-63000	USD
CY2019Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	230000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	349000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-265000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-78000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	557000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	543000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	888000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4449000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4199000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17487000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14020000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-715000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	171000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	253000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-3734000	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-4370000	USD
	us-gaap	Profit Loss ProfitLoss	-10375000	USD
	us-gaap	Profit Loss ProfitLoss	-14273000	USD
CY2020Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6000	USD
CY2019Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-3728000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-4370000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10369000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14273000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	79440000	USD
CY2019Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	39000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	543000	USD
CY2019Q3	apyx	Stock Swap To Acquire Options Amount StockSwapToAcquireOptionsAmount	0	USD
CY2019Q3	us-gaap	Profit Loss ProfitLoss	-4370000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	75652000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	66836000	USD
CY2020Q3	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	148000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	25000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1063000	USD
CY2020Q3	apyx	Stock Swap To Acquire Options Amount StockSwapToAcquireOptionsAmount	0	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-3734000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	64338000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	87177000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	154000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2594000	USD
	apyx	Stock Swap To Acquire Options Amount StockSwapToAcquireOptionsAmount	0	USD
	us-gaap	Profit Loss ProfitLoss	-14273000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	75652000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71259000	USD
	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	148000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	97000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3209000	USD
	apyx	Stock Swap To Acquire Options Amount StockSwapToAcquireOptionsAmount	0	USD
	us-gaap	Profit Loss ProfitLoss	-10375000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	64338000	USD
	us-gaap	Profit Loss ProfitLoss	-10375000	USD
	us-gaap	Profit Loss ProfitLoss	-14273000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	662000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	510000	USD
	apyx	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	427000	USD
	apyx	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	36000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-19000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3209000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2594000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	0	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	2000	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	164000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	486000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-238000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1389000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2397000	USD
	apyx	Increase Decrease In Income Tax Receivables Prepaid Expenses And Other Assets IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets	7793000	USD
	apyx	Increase Decrease In Income Tax Receivables Prepaid Expenses And Other Assets IncreaseDecreaseInIncomeTaxReceivablesPrepaidExpensesAndOtherAssets	1202000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	717000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1772000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	15000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	50000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2352000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1611000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15049000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15224000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	193000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1076000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	18884000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	80726000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-193000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	60766000	USD
	apyx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	97000	USD
	apyx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	154000	USD
	apyx	Repaymentof Finance Lease Liabilities RepaymentofFinanceLeaseLiabilities	184000	USD
	apyx	Repaymentof Finance Lease Liabilities RepaymentofFinanceLeaseLiabilities	2000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	148000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	152000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-92000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-18000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15273000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	45676000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58812000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16596000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43539000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62272000	USD
	us-gaap	Interest Paid Net InterestPaidNet	39000	USD
	us-gaap	Interest Paid Net InterestPaidNet	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	54000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	248000	USD
	apyx	Lease Adoption LeaseAdoption	0	USD
	apyx	Lease Adoption LeaseAdoption	212000	USD
	apyx	Capitalization Of Lease Non Cash CapitalizationOfLeaseNonCash	0	USD
	apyx	Capitalization Of Lease Non Cash CapitalizationOfLeaseNonCash	207000	USD
	apyx	Capitalization Of Lease Execution CapitalizationOfLeaseExecution	150000	USD
	apyx	Capitalization Of Lease Execution CapitalizationOfLeaseExecution	662000	USD
	apyx	Non Cash Transfer Of Other Assets To Fixed Assets NonCashTransferOfOtherAssetsToFixedAssets	0	USD
	apyx	Non Cash Transfer Of Other Assets To Fixed Assets NonCashTransferOfOtherAssetsToFixedAssets	42000	USD
	apyx	Non Cash Transfers Of Inventory To From Fixed Assets NonCashTransfersOfInventoryToFromFixedAssets	10000	USD
	apyx	Non Cash Transfers Of Inventory To From Fixed Assets NonCashTransfersOfInventoryToFromFixedAssets	264000	USD
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	RECENT ACCOUNTING PRONOUNCEMENTS <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments—Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the consolidated financial statements, we do not expect the impact to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU 2017-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The purpose of this ASU is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the implied fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this ASU, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit’s fair value. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted the ASU on January 1, 2020. The amendment did not have an impact on our consolidated financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div>
CY2018Q3	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	97000000	USD
CY2019Q3	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	100000	USD
	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	300000	USD
CY2020Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	2487000	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2935000	USD
CY2020Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	1522000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1209000	USD
CY2020Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1944000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1316000	USD
CY2020Q3	us-gaap	Inventory Gross InventoryGross	5953000	USD
CY2019Q4	us-gaap	Inventory Gross InventoryGross	5460000	USD
CY2020Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	537000	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	392000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	5416000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	5068000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	400000	USD
CY2020Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	497000	USD
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	694000	USD
CY2020Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	0	USD
CY2019Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1306000	USD
CY2020Q3	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	620000	USD
CY2019Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	877000	USD
CY2020Q3	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	471000	USD
CY2019Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	452000	USD
CY2020Q3	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	632000	USD
CY2019Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	1170000	USD
CY2020Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	744000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1383000	USD
CY2020Q3	apyx	Joint And Several Payroll Liability JointAndSeveralPayrollLiability	1045000	USD
CY2019Q4	apyx	Joint And Several Payroll Liability JointAndSeveralPayrollLiability	1045000	USD
CY2020Q3	apyx	Uncertain Tax Positions Liability UncertainTaxPositionsLiability	1616000	USD
CY2019Q4	apyx	Uncertain Tax Positions Liability UncertainTaxPositionsLiability	1491000	USD
CY2020Q3	apyx	Other Accrued Expenses And Liabilities Current OtherAccruedExpensesAndLiabilitiesCurrent	963000	USD
CY2019Q4	apyx	Other Accrued Expenses And Liabilities Current OtherAccruedExpensesAndLiabilitiesCurrent	978000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6588000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9396000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34216000	shares
CY2019Q4	apyx	Noncontrolling Interest Required Capital Contribution NoncontrollingInterestRequiredCapitalContribution	360000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-3728000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-4370000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10369000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14273000	USD
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34078000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34193000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34039000	shares
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1063000	USD
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3209000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	543000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2594000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3966858	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.67
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1376900	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.94
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	81131	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.03
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	234600	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	7.57
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5028027	shares
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.45
CY2020Q3	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	16140	shares
CY2019Q3	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	26572	shares
CY2020Q3	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	10610	shares
CY2019Q3	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	34928	shares
	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	29149	shares
	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	118170	shares
	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	32637	shares
	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	220879	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
	apyx	Cares Act Income Tax Expense Benefit Release Of Valuation Allowance Federal Net Operating Loss Carryforwards CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards	-3700000	USD
CY2020Q3	apyx	Cares Act Income Tax Expense Benefit Related To Current Period Net Income Loss Before Income Taxes CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes	-800000	USD
	apyx	Cares Act Income Tax Expense Benefit Related To Current Period Net Income Loss Before Income Taxes CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes	-3300000	USD
	apyx	Cares Act Federal Income Tax Payments Available To Offset Current Period Losses CARESActFederalIncomeTaxPaymentsAvailableToOffsetCurrentPeriodLosses	2400000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-715000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	171000	USD
CY2020Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.161
CY2019Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.041
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7112000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	253000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.407
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.018
CY2020Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1313000	USD
CY2020Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	300000	USD
CY2020Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	43000	USD
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	125000	USD
CY2020Q3	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1616000	USD
CY2020Q3	us-gaap	Purchase Obligation PurchaseObligation	1800000	USD
CY2020Q3	apyx	Noncontrolling Interest Required Capital Contribution NoncontrollingInterestRequiredCapitalContribution	357000	USD
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6954000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4371000	USD
CY2020Q3	us-gaap	Interest Income Operating InterestIncomeOperating	10000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	25000	USD
CY2020Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-63000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-715000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7575000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4756000	USD
CY2019Q3	us-gaap	Interest Income Operating InterestIncomeOperating	327000	USD
CY2019Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	230000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	171000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16247000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18030000	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	233000	USD
	us-gaap	Interest Expense InterestExpense	39000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	349000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7112000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19853000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14908000	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	1153000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-265000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	253000	USD
CY2020Q3	apyx	Total Revenue Percent TotalRevenuePercent	0.250
	apyx	Total Revenue Percent TotalRevenuePercent	0.248
CY2019Q3	apyx	Total Revenue Percent TotalRevenuePercent	0.267
	apyx	Total Revenue Percent TotalRevenuePercent	0.295
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6954000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7575000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16247000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	19853000	USD

Files In Submission

Name	View Source	Status
0000719135-20-000076-index-headers.html	Edgar Link	pending
0000719135-20-000076-index.html	Edgar Link	pending
0000719135-20-000076.txt	Edgar Link	pending
0000719135-20-000076-xbrl.zip	Edgar Link	pending
a2020q310-qexhibit311.htm	Edgar Link	pending
a2020q310-qexhibit312.htm	Edgar Link	pending
a2020q310-qexhibit321.htm	Edgar Link	pending
a2020q310-qexhibit322.htm	Edgar Link	pending
apyx-20200930.htm	Edgar Link	pending
apyx-20200930.xsd	Edgar Link	pending
apyx-20200930_cal.xml	Edgar Link	unprocessable
apyx-20200930_def.xml	Edgar Link	unprocessable
apyx-20200930_g1.jpg	Edgar Link	pending
apyx-20200930_htm.xml	Edgar Link	completed
apyx-20200930_lab.xml	Edgar Link	unprocessable
apyx-20200930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APYX
Apyx Medical Corp Stock $apyx

2020 Q4 Form 10-Q Financial Statement

#000071913520000076 Filed on November 09, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX Apyx Medical Corp Stock $apyx

2020 Q4 Form 10-Q Financial Statement

#000071913520000076 Filed on November 09, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX
Apyx Medical Corp Stock $apyx